Abstract

Pharmacogenomics: The End of Trial-and-Error Medicine?

Author(s): Vail Jane

Issue: Jan/Feb 2007 - Pediatric Patients

Page(s): 59-65

Download in electronic PDF format for $75
  • Pharmacogenomics: The End of Trial-and-Error Medicine? Page 1
  • Pharmacogenomics: The End of Trial-and-Error Medicine? Page 2
  • Pharmacogenomics: The End of Trial-and-Error Medicine? Page 3
  • Pharmacogenomics: The End of Trial-and-Error Medicine? Page 4
  • Pharmacogenomics: The End of Trial-and-Error Medicine? Page 5
  • Pharmacogenomics: The End of Trial-and-Error Medicine? Page 6
  • Pharmacogenomics: The End of Trial-and-Error Medicine? Page 7

Abstract

“The right dose of the right drug for the right indication for the right patient at the right time.” In those words, Dr. Felix Frueh captured the essence of pharmacogenomics and the goal of all compounding pharmacists. Pharmacogenomics provides the tools for prescribing personalized drug therapy that will improve treatment outcomes, decrease the incidence of drug-related adverse effects, and ultimately reduce the cost of medical care. The use of pharmacogenomics in clinical practice is changing as new discoveries make it possible and cost-effective to identify a patient’s unique genetic makeup and apply this information to treating medical ailments. With a prescription and the patient’s pharmacogenomic profile in mind, a compounding pharmacist can prepare a customized medication that delivers that patient’s unique best dosage in the optimal dosage form.

Related Keywords

  • PERSONALIZED MEDICINE, INDIVIDUALIZED MEDICINE, PHARMACOGENOMICS, GENOMICS, GENOME, GENETIC TESTING, RESEARCH, FDA, US FOOD AND DRUG ADMINISTRATION, TRIAL, CUSTOMIZED, JANET WOODCOCK

Related Categories

  • LEGAL
  • TECHNOLOGY
  • PROFESSIONAL ISSUES
  • PREVENTIVE MEDICINE/WELLNESS

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy		 Title/Author
(Click for Abstract / Details / Purchase)
Jan/Feb 2007
Pg. 59-65
Pharmacogenomics: The End of Trial-and-Error Medicine?
Author(s): Vail Jane
Mar/Apr 2018
Pg. 108-121
Personalized Medicine and Customized Drug Delivery Systems: The New Trend of Drug Delivery and Disease Management
Author(s): Soni Abhishek, Gowthamarajan Kuppusamy, Radhakrishnan Arun
Nov/Dec 2022
Pg. 474-479
Pharmacogenomics as a Competitive Strategy for Compounding Pharmacies
Author(s): Maham Nicole Y
Jul/Aug 2015
Pg. 280-287
Biotechnology, Nanotechnology, and Pharmacogenomics and Pharmaceutical Compounding, Part 2
Author(s): Allen Loyd V
Mar/Apr 2018
Pg. 95-107
Pharmacogenomics: Precision Pharmacy in 503A Compounding
Author(s): Drummond Joseph, Bennet Daron, Allen Loyd V Jr
Jul/Aug 2020
Pg. 296-297
Finally: A Final U.S. Food and Drug Administration Memorandum of Understanding, but It's Flawed
Author(s): Brunner Scott
Jul/Aug 2016
Pg. 351
View Sample
Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines
Author(s): Allen Loyd V Jr
Sep/Oct 2017
Pg. 356
PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs
Author(s): Allen Loyd V Jr
Jul/Aug 2015
Pg. 303-305
U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances
Author(s): Miller David G
Nov/Dec 2003
Pg. 441-447
Single-Patient Trials, Extemporaneously Compounded Products and Pharmaceutical Care
Author(s): Fassett William E
Nov/Dec 2015
Pg. 487-488
U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs
Author(s): Allen Loyd V Jr
Jan/Feb 2019
Pg. 32-33
U.S. Food and Drug Administration Inspection Authority: How to Know Whether U.S. Food and Drug Administration Inspectors Are Crossing the Line
Author(s): Snow Stephen T, Stannard Robert W, Bellis Jennifer, Moss Carrie A
Jul/Aug 2013
Pg. 307-311
Quality Control Analytical Methods: End-preparation Assessments and Tests for Compounded Sterile Preparations
Author(s): McElhiney Linda F
May/Jun 2014
Pg. 208
The U.S. Food and Drug Administration Responds to the International Academy of Compounding Pharmacists' Outsourcing Letter
Author(s): Miller David G
Mar/Apr 2017
Pg. 95-102
U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies
Author(s): Yoch Doug
Jan/Feb 2023
Pg. 24-29
Basics: A Review: In Situ Gel Dosage Forms for Herbal Medicine Delivery
Author(s): Rachmawati Putriana
Jan/Feb 2023
Pg. 22-23
The U.S. Food and Drug Administration Takes Aim at Compounded Thyroid Hormone
Author(s): Brunner Scott
Mar/Apr 2016
Pg. 155-158
Utilization of Compounded Medications in an Oral Medicine Practice
Author(s): Stock Shannon, Rubino Katie, Woo Sook-Bon, Margolis Arthur, Thomas Irena, Aboalela Ali, Treister Nathaniel
Jul/Aug 2007
Pg. 326-327
Standard Operating Procedure: U.S. Food and Drug Administration Inspection--Releasing a Sample to the U.S. Food and Drug Administration
Author(s): Kupiec Tom, Kemp Jesse
Jul/Aug 2005
Pg. 303-306
Basics of Pharmacogenomics for the Compounding Pharmacist
Author(s): Kupiec Thomas C, Raj Vishnu